hme

What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?

Agenda

Learning objective:

After participating in this webinar, viewers should be able to:

  • Explain what the key drivers are when selecting RRMM patients for treatment with bispecific antibodies

 

Faculty:

  • Michel Delforge (Belgium)
  • Paula Rodriguez-Otero (Spain)
  • Philippe Moreau (France)

 

More Info
45 Minutes
EM-93607 - Date of preparation: March 2022